Advanced imaging tools for childhood tuberculosis: potential applications and research needs
- PMID: 32589869
- PMCID: PMC7606757
- DOI: 10.1016/S1473-3099(20)30177-8
Advanced imaging tools for childhood tuberculosis: potential applications and research needs
Abstract
Tuberculosis is the leading cause of death globally that is due to a single pathogen, and up to a fifth of patients with tuberculosis in high-incidence countries are children younger than 16 years. Unfortunately, the diagnosis of childhood tuberculosis is challenging because the disease is often paucibacillary and it is difficult to obtain suitable specimens, causing poor sensitivity of currently available pathogen-based tests. Chest radiography is important for diagnostic evaluations because it detects abnormalities consistent with childhood tuberculosis, but several limitations exist in the interpretation of such results. Therefore, other imaging methods need to be systematically evaluated in children with tuberculosis, although current data suggest that when available, cross-sectional imaging, such as CT, should be considered in the diagnostic evaluation for tuberculosis in a symptomatic child. Additionally, much of the understanding of childhood tuberculosis stems from clinical specimens that might not accurately represent the lesional biology at infection sites. By providing non-invasive measures of lesional biology, advanced imaging tools could enhance the understanding of basic biology and improve on the poor sensitivity of current pathogen detection systems. Finally, there are key knowledge gaps regarding the use of imaging tools for childhood tuberculosis that we outlined in this Personal View, in conjunction with a proposed roadmap for future research.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests
SKJ reports grants from US National Institutes of Health (NIH) and grants from US Department of Defense’s Congressionally Directed Medical Research Programs, during the conduct of the study; SKJ has a pending patent (PCT/US13/059897) on bacteria-specific labelled substrates as imaging biomarkers, filed by Johns Hopkins University. JRS is a member of a Data Safety Monitoring Board for Otsuka Pharmaceuticals for the paediatric pharmacologic studies of delamanid, a new drug used for multidrug-resistant tuberculosis. AAO has a patent pending (PCT/US13/059897) on bacteria-specific labelled substrates as imaging biomarkers, filed by Johns Hopkins University. The views expressed by speakers and panellists at the Department of Health and Human Services (DHHS) sponsored workshops do not necessarily reflect the official policies of the DHHS. SKJ and AAO also receive support from the NIH (Director’s Transformative Research Award R01-EB020539, R01-HL131829, R01-EB025985, R01-AI145435-A1, and R21-AI149760), the Department of Defense’s Congressionally Directed Medical Research Programs PR-171338P1. SAnt receives support from the Intramural Research Program of the National Library of Medicine, NIH. All other authors declare no competing interests.
Figures
References
-
- Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis 2010; 50: S184–94. - PubMed
-
- Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med 2012; 367: 348–61. - PubMed
-
- Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health 2014; 2: e453–59. - PubMed
-
- WHO. Global tuberculosis report 2019. https://www.who.int/tb/publications/global_report/tb19_Exec_Sum_15Octobe... (accessed Feb 21, 2020).
